Compare Amylx Pharmaceuticals Inc (AMLX) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Nomura Holdings Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.29 (market cap $1.98B), while Nomura Holdings Inc trades at $9.62 (market cap $27.88B). The key difference: Nomura Holdings Inc is far larger — about 14.1× Amylx Pharmaceuticals Inc's market cap, and Nomura Holdings Inc pays a 3.35% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NMR | |
|---|---|---|
Market Cap | $1.98B | $27.88B |
Sector | Health | Financials |
52-Week High | $18.70 | $9.66 |
52-Week Low | $7.64 | $6.30 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Nomura Holdings (NMR) trades at $9.66, up 1.26% today, with a bullish technical signal from moving averages. The company reported record annual revenue of $1.66 trillion and net income of $340.74 billion for 2025, driving a net income margin of 20.49%. Recent news highlights strong wholesale revenue growth and strategic acquisitions, while analyst consensus shows a hold-heavy rating with 33% buy recommendations.
The outlook is mixed; robust profitability and expansion in core segments support upside, but consecutive earnings misses and rising debt-to-asset ratios pose risks. Investor sentiment is cautiously optimistic, with technical indicators suggesting near-term momentum but overbought conditions on shorter-term RSI readings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
